P8A:SGX
Cordlife Group Ltd
SGD ०.१२
०.००%
(०.००) 1D
अक्टोबर १२, ०९:४९:२० GMT+८ · SGD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for P8A...
Mkt. cap
३.२४ करोड
Avg. vol.
१.३२ हजार
Volume
०.००
52-wk high
SGD ०.२६
52-wk low
SGD ०.१०
EPS
-SGD ०.०४
Shares outstanding
२६.७५ करोड
No. of employees
१११
Mkt. cap
३.२४ करोड
Avg. vol.
१.३२ हजार
Volume
०.००
52-wk high
SGD ०.२६
52-wk low
SGD ०.१०
EPS
-SGD ०.०४
Shares outstanding
२६.७५ करोड
No. of employees
१११
News stories
From web sources and news partners
AskTraders.com
·
५१ मिनेट पहिले
S&P 500 Can Absorb Fed Hikes, Says UBS CIO After Hot US Inflation
Traders Union
·
१ घण्टा पहिले
Peter Tuchman: Nasdaq posts worst week since April 2025 tariff selloff as S&P 500 loses $1.3 trillion
Yahoo Finance
·
१० घण्टा पहिले
Michael Burry Warns of a Stock Market ‘Supervolcano’
AOL.com
·
६ घण्टा पहिले
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
Profile
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
About Cordlife Group Ltd